N/A N=500 Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
Gram-negative Bacteremia
Primary: Hours to First Antibiotic Modification — 24.7; 19.0 hours — p=0.013
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Phase 4 N=85 Negative Beta Glucan in ICU Patients
Candidemia
Primary: Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin — 0; 21 Participants
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
N/A N=72 Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).
Bile Duct Stricture · Choledocholithiasis
Primary: Number of Patients With Bacteremia — 25; 20; 5; 10 Participants
N/A N=100 Modified Reporting of Positive Urine Cultures Collected From Long Term Care
Urinary Tract Infections · Asymptomatic Bacteriuria
Primary: Proportion of Asymptomatic Bacteriuria Treated With Antibiotics and Urinary Tract Infection Treated With Antibiotics — 31; 25 Participants
N/A N=121 Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis
Sepsis
Primary: Antibiotic Treatment for More Than 72 Hours — 33; 55 participants — p=0.002
Phase 3 N=68 Group B Streptococcus Response After Probiotic Exposure
Group B Strep Infection
Primary: GBS Culture Result (Positive Versus Negative) — 3; 6; 18; 19 Participants
Phase 3 N=16 The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Gram-Negative Bacterial Infections · Sepsis
Primary: Number of Participants Not Requiring Renal Replacement Therapy (RRT) — 3; 1 participants
N/A N=743 Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures
Bacteremia · Fungemia · Bloodstream Infection
Primary: Duration of Antimicrobial Therapy (Hours) — 44; 42; 42; 8.2 hours — p=0.92
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants
Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
N/A N=260 MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants
Open Reduction and Internal Fixation of Extremity Fractures
Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples
N/A N=150 Bacterial Translocation Markers as Predictors of Infectious and Inflammatory Complications in Acute Bowel Obstruction
Intestinal Obstruction · Colorectal Cancer · Post-Op Complication
Primary: Change in Number of Participants With Post-operative Infectious and Inflammatory Complications — 43; 47; 25; 17 Participants
N/A N=65 Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants
Preterm Infant · Early-Onset Neonatal Sepsis · Umbilical Cord
Primary: White Blood Cell Count (WBC) (1) — 8257 ratio of cells/mm3
N/A N=22 Piperacillin PK Analysis in Severe Sepsis Patients
Sepsis · Severe Sepsis
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 4 participants
Phase 4 N=60 Management of Sub-Clinical Bacteriuria in Pregnancy
Cystitis · Cystitis;Puerperium · Pyelonephritis
Primary: Number of Participants Who Have Cystitis — 4; 4 Participants
N/A N=479 Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala
Bacteremia · Sepsis
Primary: Time to Optimal Antimicrobial Therapy — 31.1; 117.7; 90.0 hours
Phase 2 N=39 Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
Infection · Bacteremia
Primary: Patient Clinical Response to Telavancin — 32 Participants
N/A N=3,723 Three-Chamber Bags Retrospective Study in Spain
Parenteral Nutrition · Blood Stream Infection
Primary: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB) — 127; 106 Participants
Phase 3 N=390 Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia
Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants
Phase 4 N=103 The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria
Infectious Disease of Digestive Tract
Primary: Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE — 8; 8 Participants
Phase 2 N=56 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…
N/A N=15 PK Analysis of Piperacillin in Septic Shock Patients
Septic Shock
Primary: 100% f T>MIC: Free Piperacillin Concentration Maintained Above the MIC Throughout the Dosing Interval. — 10 participants
Phase 4 N=12 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
Febrile Neutropenia
Primary: Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients — 36.7; 49.9; 43.9 Liters
N/A N=142 BBOT: Bacterial Burden in Ortho Trauma Procedures
Orthopaedic Trauma Infections
Primary: Number of Participants With Tissue Samples Identified With Bacterial DNA According to Highly Sensitive Bacterial Assays — 10; 24; 20 Participants
Phase 2 N=60 Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Gram-Positive Bacterial Infections
Primary: Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With…
N/A N=214 Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Encephalitis · Meningitis
Primary: Total Number of Cases With at Least One Provider Response — 98; 58 cases
Phase 2 N=121 Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants